Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 13/20 | 0.45 |
| ▸ | PDE4A | P27815 | 11/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 11/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | PDE1A | P54750 | 1/20 | 0.41 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.41 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19083723 | 0.90 | PDE4D (0.53) | PDE4DPDE4APDE4BPDE4CEPHX2 | |
| SCHEMBL1976483 | 0.77 | EPHX2 (0.47) | EPHX2HRH3 | |
| SCHEMBL5675701 | 0.73 | TSHR (0.60) | TAS1R3TAS1R1 | |
| SCHEMBL20021951 | 0.72 | PDE4B (0.54) | PDE4DPDE4APDE4BPDE4CEPHX2 | |
| SCHEMBL28047777 | 0.72 | PDE4B (0.60) | PDE4DPDE4APDE4BPDE4CEPHX2 | |
| SCHEMBL15030530 | 0.72 | PDE4B (0.50) | PDE4DPDE4APDE4BPDE4CEPHX2 | |
| SCHEMBL16806651 | 0.70 | PDE4B (0.51) | PDE4DPDE4APDE4BPDE4CEPHX2 | |
| SCHEMBL10088647 | 0.69 | PDE4B (0.52) | PDE4DPDE4APDE4BPDE4CHRH3 | |
| SCHEMBL25453516 | 0.69 | HRH3 (0.49) | PDE4DPDE4APDE4BPDE4CEPHX2 | |
| SCHEMBL1981191 | 0.69 | DGAT2 (0.53) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | PDE4D 461/4885PDE4A 449/4885PDE4B 452/4885 |
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | PDE4D 461/4885PDE4A 449/4885PDE4B 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.